While most of us are familiar with type 1 and type 2 diabetes, you may not have come across the term ‘type 3 diabetes’ before.

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

A new study has found that micronutrient deficiency—low levels of essential vitamins and minerals—is common in people with ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

New research found that working out starts a chain reaction that can lower your risk of dementia. Here's exactly how it works ...

Cardiovascular diseases claim more lives in the U.S. than all forms of cancer and accidental deaths combined, according to ...

“There are some studies that show a lot of actually nutrition benefits to coffee,” said registered dietitian Ashley Hinds. A ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.